Table 1. GEO data sets used in the study and number of patients in each data set.
| GEO accession number | Regimen | Total | ||
|---|---|---|---|---|
| Anthracycline (A) | Paclitaxel and Anthracycline (TA) | Docetaxel and Anthracycline (TxA) | ||
| GSE2019443 | 4 (0) | 257 (20.6%) | 8 (12.5%) | 269 (20.1%) |
| GSE2027144 | 85 (8.2%) | 91 (20.9%) | — | 176 (14.8%) |
| GSE2209345 | 50 (10%) | — | — | 50 (10%) |
| GSE2398845 | — | — | 61 (32.8%) | 61 (32.8%) |
| GSE2505513 | — | 290 (18.3%) | — | 290 (18.3%) |
| GSE2506513 | — | 92 (20.7%) | 88 (26.1%) | 180 (23.3%) |
| GSE4282246 | — | — | 53 (37.7%) | 53 (37.7%) |
| Total | 139 (8.6%) | 730 (19.7%) | 210 (30.5%) | 1079 (20.4%) |
Values in parenthesis are percentage of patients who have pCR among the patients in the corresponding regimen group. The rest of the patients have RD. All the patients were put into one of three regimen groups based on the treatment each patient received: anthracycline alone (A), paclitaxel and anthracycline (TA), and docetaxel and anthracycline (TxA).